Nuomedis ^None

Nuomedis AG is a Swiss joint-stock company founded in 2014 by Dr. Marko Loparic and Nanosurf AG. Its main focus is on developing a clinical grade device that measures the stiffness of diseased tissue and uses nanomechanical cancer diagnostics applications. The company aims to empower physicians worldwide with nanomechanical tissue diagnostics and prognostics. Nuomedis is developing the first clinical grade instrument that measures the nanomechanical fingerprint of cancer, which will lead to better adjusted treatment options for patients.